Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer

Breast Cancer Research and Treatment

Volumn 99, Issue 1, 2006, Pages 77-83

  Neri, Alessandro ^a   Marrelli, Daniele ^a   Roviello, Franco ^a   DeMarco, Giovanni ^a   Mariani, Federico ^a   DeStefano, Alfonso ^a   Megha, Tiziana ^a   Caruso, Stefano ^a   Corso, Gianni ^a   Cioppa, Tommaso ^a   Pinto, Enrico ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

bcl 2 genes; Breast neoplasm genes; Multivariate analysis; p53; Prognosis; Prospective studies

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER INVASION; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; COURSE EVALUATION; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HOSPITAL DEPARTMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TISSUE SECTION; UNIVARIATE ANALYSIS;

ADULT; AGED; APOPTOSIS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33746738134     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9183-2     Document Type: Article

References (32)

1. Cianfrocca M, Goldstein LJ: Prognostic and predictive factors in early breast cancer. Oncologist 9: 606-616, 2004
2. Frassoldati A, Maur M, Guarneri V, Nicolini M, Conte PF: Predictive value of biologic parameters for primary chemotherapy in operable breast cancer. Clin Breast Cancer 6: 315-324, 2005
3. Meterissian SH: Apoptosis: its role in the progression of and chemotherapy for carcinoma. J Am Coll Surg 184: 658-666, 1997
4. Krajewski S, Krajewska M, Turner BC, Pratt C, Howard B, Zapata JM, Frenkel V, Robertson S, Ionov Y, Yamamoto H, Perucho M, Takayama S, Reed JC: Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 6: 29-40, 1999
5. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102: 13,550-13,555, 2005
6. Silvestrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, Salvatori B, Veronesi U: Validation of p53 accumulation as a predictor of distant metastases at 10 years of follow-up in 1400 node negative breast cancers. Clin Cancer Res 2: 2007-2013, 1996
7. Elledge RM, Allred DC: Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 52: 79-98, 1998
8. Pharoah PD, Day NE, Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Brit J Cancer 80: 1968-1973, 1999
9. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H: Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6: 24-30, 2004
10. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992
11. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991
12. Silvestrini R, Veneronis S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U: The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499, 1994
13. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC: Bcl-2 and apoptosis in lymphnode positive breast carcinoma. Cancer 82: 1296-1302, 1998
14. Barbareschi M, Caffo O, Veronese E, Leek RD, Fina P, Fox S, Bolzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Della Palma C, Harris A: Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol 27: 1149-1155, 1996
15. Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S: Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 198: 83-90, 2004
16. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC: Cloning and functional analysis of BAG-1: a novel bcl-2 binding protein with anti-cell death activity. Cell 80: 2279-2284, 1995
17. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993
18. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ: Bad, a heterodimeric partner for bcl-xL and bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291, 1995
19. Sobin LH, Wittekind C: TNM classification of malignant tumors. 6th edn. John Wiley & Sons (ed), New York, 2002
20. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991
21. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR, Dowsett M: Reduced apoptosis and proliferation and increased bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48: 107-116, 1998
22. Norberg T, Jansson T, Sjogren S, Martensson C, Andreasson I, Fjallskog ML, Lindman H, Nordgren H, Lindgren A, Holmberg L, Bergh J: Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumor suppressor gene p53. Acta Oncol 35: 96-102, 1996
23. Jager JJ, Janse LH, Arends JW: Clinical relevance of apoptotic markers in breast cancer not yet clear. Apoptosis 7: 361-365, 2002
24. Rozan S, Vincent-Salomon A, Zafrani B, Validire P, De Cremoux P, Bernoux A, Nieruchalski M, Fourquet A, Clough K, Dieras V, Pouillart P, Sastre-Garau X: No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79: 27-33, 1998
25. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259-1266, 1995
26. Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Patsouris E, Asimacopoulos P, Gorgoulis VG: Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. Anticancer Res 24: 2061-2068, 2004
27. Hartmann A, Blaszyk H, McGovern RM, Schroeder JJ, Cunningham J, De Vries EM, Kovach JS, Sommer SS: p53 gene mutations inside and outside of exons 5-8: the pattern differs in breast and other cancers. Oncogene 10: 681-688, 1995
28. Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, Mc Ready DR, Andrulis IR: The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 22: 86-96, 2004
29. Kymionis GD, Dimitrikakis CE, Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G, Keramopoulos A, Michalas S: Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node negative breast cancer patients? J Surg Res 99: 161-168, 2001
30. Yang Q, Sakurai T, Yoshimura G, Suzuma T, Umemura T, Nakamura M, Mori I, Kaduko K: Prognostic value of bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol Rep 10: 121-125, 2003
31. Knowlton K, Mancini M, Creason S, Morales C, Hockenbery D, Anderson BO: Bcl-2 slows in vitro breast cancer growth despite its anti-apoptotis effect. J Surg Res 81: 387-392, 1998
32. Woo CS, Silberman H, Nakamura SK, Ye W, Sposto R, Colburn W, Waisman JR, Silverstein MJ: Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer. Am J Surg 184: 337-340, 2002